cas 123344-02-5|| where to buy 2,4-Difluoro-5-nitroaniline

Product Name:2,4-Difluoro-5-nitroaniline

IUPAC Name:2,4-difluoro-5-nitroaniline

Packing Unit	Available Stock	Price($)
CM118614-5g	in stock	ƞź
CM118614-10g	in stock	Ǌưƞ
CM118614-25g	in stock	ȎǊư
CM118614-100g	1-2 Weeks	ƞŉư

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 123344-02-5 regularly via the above email.

Additional Notes

Verification code*

refresh

: CAS NO:123344-02-5; Molecular Formula:C6H4F2N2O2; Melting Point:-; Smiles Code:NC1=CC([N+]([O-])=O)=C(F)C=C1F; Density:

: Catalog Number:CM118614; Molecular Weight:174.11; Boiling Point:; MDL No:MFCD04038395; Storage:Keep in dark place, store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Osimertinib; TAGRISSO (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial.
TAGRISSO (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. It is the first and only EGFR TKI recommended by NCCN Guidelines as an adjuvant treatment option for completely resected stage IB-IIIA, stage IIIB (T3, N2) EGFRm (exon 19 deletion, exon 21 L858R mutation) NSCLC.